Depression - Pipeline Review, H2 2018

Depression - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H2 2018, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 16, 33, 30, 76, 12 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 7 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 7
Depression - Overview 8
Depression - Therapeutics Development 9
Depression - Therapeutics Assessment 32
Depression - Companies Involved in Therapeutics Development 47
Depression - Drug Profiles 86
Depression - Dormant Projects 449
Depression - Discontinued Products 466
Depression - Product Development Milestones 471
Appendix 484

List Of Tables


Number of Products under Development for Depression, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Depression - Pipeline by Acadia Pharmaceuticals Inc, H2 2018
Depression - Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2018
Depression - Pipeline by Adamed Sp z oo, H2 2018
Depression - Pipeline by Addex Therapeutics Ltd, H2 2018
Depression - Pipeline by Aequus Pharmaceuticals Inc, H2 2018
Depression - Pipeline by Albany Molecular Research Inc, H2 2018
Depression - Pipeline by Alkermes Plc, H2 2018
Depression - Pipeline by Allergan Plc, H2 2018
Depression - Pipeline by Amorsa Therapeutics Inc, H2 2018
Depression - Pipeline by Anavex Life Sciences Corp, H2 2018
Depression - Pipeline by Avanir Pharmaceuticals Inc, H2 2018
Depression - Pipeline by Axsome Therapeutics Inc, H2 2018
Depression - Pipeline by Azevan Pharmaceuticals Inc, H2 2018
Depression - Pipeline by BioCrea GmbH, H2 2018
Depression - Pipeline by Bionomics Ltd, H2 2018
Depression - Pipeline by BioXcel Therapeutics Inc, H2 2018
Depression - Pipeline by Blackthorn Therapeutics Inc, H2 2018
Depression - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Depression - Pipeline by Bristol-Myers Squibb Co, H2 2018
Depression - Pipeline by Calico LLC, H2 2018
Depression - Pipeline by Celgene Corp, H2 2018
Depression - Pipeline by Cellix Bio Pvt Ltd, H2 2018
Depression - Pipeline by Celon Pharma SA, H2 2018
Depression - Pipeline by Cerecor Inc, H2 2018
Depression - Pipeline by Clera Inc, H2 2018
Depression - Pipeline by Delpor Inc, H2 2018
Depression - Pipeline by DURECT Corp, H2 2018
Depression - Pipeline by Eisai Co Ltd, H2 2018
Depression - Pipeline by Eli Lilly and Co, H2 2018
Depression - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2018
Depression - Pipeline by FPRT Bio Inc, H2 2018
Depression - Pipeline by GlaxoSmithKline Plc, H2 2018
Depression - Pipeline by GliaCure Inc, H2 2018
Depression - Pipeline by H. Lundbeck AS, H2 2018
Depression - Pipeline by Heptares Therapeutics Ltd, H2 2018
Depression - Pipeline by Impel NeuroPharma Inc, H2 2018
Depression - Pipeline by Intas Pharmaceuticals Ltd, H2 2018
Depression - Pipeline by IntelGenx Corp, H2 2018
Depression - Pipeline by Intra-Cellular Therapies Inc, H2 2018
Depression - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2018
Depression - Pipeline by Johnson & Johnson, H2 2018
Depression - Pipeline by Karuna Pharmaceuticals Inc, H2 2018
Depression - Pipeline by KemPharm Inc, H2 2018
Depression - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018
Depression - Pipeline by Lead Discovery Center GmbH, H2 2018
Depression - Pipeline by Les Laboratoires Servier SAS, H2 2018
Depression - Pipeline by Lixte Biotechnology Holdings Inc, H2 2018
Depression - Pipeline by Luye Pharma Group Ltd, H2 2018

List Of Figures


Number of Products under Development for Depression, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Treatment Resistant Depression Global Clinical Trials Review, H2, 2018

Treatment Resistant Depression Global Clinical Trials Review, H2, 2018The clinical trial report, Treatment Resistant Depression Global Clinical Trials Review, H2, 2018 provides an overview of Treatment Resistant Depression clinical trials

USD 2500 View Report

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018This report provides an overview of the pipeline landscape for depression and anxiety disorders. It provides comprehensive information on the therapeutics under

USD 3995 View Report

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2018T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T

USD 3500 View Report

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H2 2018Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4

USD 3500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available